Jaguar Health (NASDAQ:JAGX) Now Covered by StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Jaguar Health (NASDAQ:JAGX) in a research note issued to investors on Monday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Jaguar Health Stock Down 11.4 %

Shares of Jaguar Health stock opened at $0.16 on Monday. The company has a current ratio of 2.00, a quick ratio of 1.34 and a debt-to-equity ratio of 6.33. The company has a 50-day simple moving average of $0.09 and a two-hundred day simple moving average of $0.18. Jaguar Health has a one year low of $0.05 and a one year high of $1.22.

Hedge Funds Weigh In On Jaguar Health

Large investors have recently added to or reduced their stakes in the company. Citigroup Inc. bought a new position in Jaguar Health in the first quarter worth about $34,000. Goldman Sachs Group Inc. raised its holdings in Jaguar Health by 153.3% in the first quarter. Goldman Sachs Group Inc. now owns 54,770 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 33,148 shares in the last quarter. Acadian Asset Management LLC bought a new position in Jaguar Health in the first quarter worth about $43,000. Geode Capital Management LLC acquired a new position in shares of Jaguar Health during the second quarter valued at about $48,000. Finally, Bank of New York Mellon Corp increased its holdings in shares of Jaguar Health by 507.3% during the first quarter. Bank of New York Mellon Corp now owns 169,749 shares of the biotechnology company’s stock valued at $120,000 after acquiring an additional 141,796 shares in the last quarter. 12.04% of the stock is currently owned by institutional investors.

About Jaguar Health

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.